140 related articles for article (PubMed ID: 38170793)
21. NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens.
Borden ES; Ghafoor S; Buetow KH; LaFleur BJ; Wilson MA; Hastings KT
J Immunol; 2022 Apr; 208(7):1813-1827. PubMed ID: 35304420
[TBL] [Abstract][Full Text] [Related]
22. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
23. dbPepNeo: a manually curated database for human tumor neoantigen peptides.
Tan X; Li D; Huang P; Jian X; Wan H; Wang G; Li Y; Ouyang J; Lin Y; Xie L
Database (Oxford); 2020 Jan; 2020():. PubMed ID: 32090262
[TBL] [Abstract][Full Text] [Related]
24. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
[TBL] [Abstract][Full Text] [Related]
25. neoANT-HILL: an integrated tool for identification of potential neoantigens.
Coelho ACMF; Fonseca AL; Martins DL; Lins PBR; da Cunha LM; de Souza SJ
BMC Med Genomics; 2020 Feb; 13(1):30. PubMed ID: 32087727
[TBL] [Abstract][Full Text] [Related]
26. TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification.
Tang Y; Wang Y; Wang J; Li M; Peng L; Wei G; Zhang Y; Li J; Gao Z
BMC Bioinformatics; 2020 Nov; 21(1):532. PubMed ID: 33208106
[TBL] [Abstract][Full Text] [Related]
27. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
28. Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma.
Jiang C; Schaafsma E; Hong W; Zhao Y; Zhu K; Chao CC; Cheng C
Front Immunol; 2021; 12():703821. PubMed ID: 35111147
[TBL] [Abstract][Full Text] [Related]
29.
Zhang Z; Zhou C; Tang L; Gong Y; Wei Z; Zhang G; Wang F; Liu Q; Yu J
Aging (Albany NY); 2020 Jul; 12(14):14633-14648. PubMed ID: 32697765
[TBL] [Abstract][Full Text] [Related]
30. Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma.
Wang Y; Jin B; Zhou N; Sun Z; Li J; Chen Q; Wu X; Zhou Y; Shi Y; Lu X; Sang X; Mao Y; Du S; Wang W; Bai C
Curr Cancer Drug Targets; 2020; 20(11):875-886. PubMed ID: 32957886
[TBL] [Abstract][Full Text] [Related]
31. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
[TBL] [Abstract][Full Text] [Related]
32. Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines.
Aguilar-Gurrieri C; Barajas A; Rovirosa C; Ortiz R; Urrea V; de la Iglesia N; Clotet B; Blanco J; Carrillo J
Cancer Immunol Immunother; 2023 Jul; 72(7):2113-2125. PubMed ID: 36820900
[TBL] [Abstract][Full Text] [Related]
33. Sources of Cancer Neoantigens beyond Single-Nucleotide Variants.
Capietto AH; Hoshyar R; Delamarre L
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077528
[TBL] [Abstract][Full Text] [Related]
34. Neoantigens in Hematologic Malignancies.
Biernacki MA; Bleakley M
Front Immunol; 2020; 11():121. PubMed ID: 32117272
[TBL] [Abstract][Full Text] [Related]
35. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39
Liu T; Tan J; Wu M; Fan W; Wei J; Zhu B; Guo J; Wang S; Zhou P; Zhang H; Shi L; Li J
Gut; 2021 Oct; 70(10):1965-1977. PubMed ID: 33262196
[TBL] [Abstract][Full Text] [Related]
36. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
37. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
38. T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy.
Sim MJW; Sun PD
Front Immunol; 2022; 13():833017. PubMed ID: 35222422
[TBL] [Abstract][Full Text] [Related]
39. Neodb: a comprehensive neoantigen database and discovery platform for cancer immunotherapy.
Wu T; Chen J; Diao K; Wang G; Wang J; Yao H; Liu XS
Database (Oxford); 2023 Jun; 2023():. PubMed ID: 37311149
[TBL] [Abstract][Full Text] [Related]
40. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
